Dexmedetomidine for Pain Reduction in CABG

• Status: Not yet recruiting
• Trial end date: 2024-05-09
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether adjuvant intravenous dexmedetomidine infusion starting after induction of general anesthesia can provide superior pain management (decrease pain scores) and decrease opioid administration, without increasing nausea/vomiting, compared to patients receiving only opioid and acetaminophen for the patients which going through coronary artery bypass grafting (CABG)?

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wayne State University
• Treatments: Dexmedetomidine; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Patients will be between 18 years old and 100 years old. Both men and women will be eligible for this study. We will aim to have approximately 50% men and 50% women. People of all races and ethnic origins are eligible.

Patients should be undergoing CABG (coronary artery bypass grafting ) under general anesthesia with CPB (Cardiopulmonary bypass).

Exclusion Criteria:

Patients will be excluded who are receiving valve replacement with CABG, Class I emergent CABG, receiving regional anesthesia, clinically significant preoperative neurologic, cardiac, pulmonary, renal, or hepatic disease that cannot tolerate dexmedetomidine infusion, or reported allergy to dexmedetomidine. People taking chronic opioid will also be excluded from the study.